866-997-4948(US-Canada Toll Free)

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 27 Pages

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016, provides in depth analysis on Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted pipeline therapeutics.

The report provides comprehensive information on the Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10)
- The report reviews Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics and enlists all their major and minor projects
- The report assesses Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) Overview 5
Therapeutics Development 6
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Products under Development by Stage of Development 6
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Products under Development by Therapy Area 7
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Products under Development by Indication 8
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Products Glance 9
Early Stage Products 9
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Products under Development by Companies 10
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Products under Development by Universities/Institutes 12
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Companies Involved in Therapeutics Development 18
Crestone Inc 18
TSRL Inc 19
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Drug Profiles 20
BXN-112 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
BXN-113 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
CRS-3123 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Small Molecules to Inhibit Methionyl-tRNA Synthetase for Gram Positive Bacterial Infections - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Featured News & Press Releases 25
Jul 09, 2014: NIH Launches Phase I Clinical Trial of Novel Drug to Treat Clostridium difficile Infection 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

List of Tables
Number of Products under Development for, H2 2016 6
Number of Products under Development by Therapy Area, H2 2016 7
Number of Products under Development by Indication, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17
Pipeline by Crestone Inc, H2 2016 18
Pipeline by TSRL Inc, H2 2016 19

List of Figures
Number of Products under Development for, H2 2016 6
Number of Products under Development by Indication, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 9
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *